Genetic basis of drug-induced liver injury: Present and future

Seminars in Liver Disease

Volumn 34, Issue 2, 2014, Pages 123-133

  Urban, Thomas J ^a   Daly, Ann K ^b   Aithal, Guruprasad P ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c NIHR NOTTINGHAM BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

Author keywords

ABC transporter; candidate gene study; cytochrome P450; genome wide association study; human leukocyte antigen; N acetyltransferase; UDP glucuronosyltransferase

Indexed keywords

ABC TRANSPORTER; ACYLTRANSFERASE; AMOXICILLIN PLUS CLAVULANIC ACID; CLOMETACIN; CYTOCHROME P450; FLUCLOXACILLIN; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; ISONIAZID; LAPATINIB; LUMIRACOXIB; NEVIRAPINE; PYRAZINAMIDE; RIFAMPICIN; TICLOPIDINE; TIOPRONIN; XIMELAGATRAN; HLA ANTIGEN; PEPTIDE ALPHA N ACETYLTRANSFERASE;

ALLELE; ARTICLE; DISEASE PREDISPOSITION; DNA SEQUENCE; DRUG DISPOSITION; DRUG METABOLISM; EPIGENETICS; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HLA SYSTEM; HUMAN; OXIDATIVE STRESS; PHARMACOGENETICS; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; RISK FACTOR; RNA TRANSLATION; TOXIC HEPATITIS; DRUG INACTIVATION; GENETIC PREDISPOSITION; GENETICS; METABOLISM;

ATP-BINDING CASSETTE TRANSPORTERS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG-INDUCED LIVER INJURY; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; HLA ANTIGENS; HUMANS; INACTIVATION, METABOLIC; N-TERMINAL ACETYLTRANSFERASES; OXIDATIVE STRESS; PHARMACOGENETICS;

EID: 84901768135     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0034-1375954     Document Type: Article

References (101)

1. Wilke R. A., Lin D. W., Roden D. M., et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov: 2007; 6 11 904 916 (Pubitemid 350042398)
2. Ostapowicz G., Fontana R. J., Schiodt F. V., et al. U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med: 2002; 137 12 947 954 (Pubitemid 35440240)
3. Meyer U. A. Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. Nat Rev Genet: 2004; 5 9 669 676 (Pubitemid 39150124)
4. Urban T. J., Shen Y., Stolz A., et al. Drug-Induced Liver Injury Network; DILIGEN; EUDRAGENE; Spanish DILI Registry; International Serious Adverse Events Consortium. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics: 2012; 22 11 784 795
5. Wellcome Trust Case Control C.; Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature: 2007; 447 7145 661 678
6. McCarthy M. I., Abecasis G. R., Cardon L. R., et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet: 2008; 9 5 356 369 (Pubitemid 351556063)
7. Daly A. K., Donaldson P. T., Bhatnagar P., et al. DILIGEN Study; International SAE Consortium. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet: 2009; 41 7 816 819
8. Monshi M. M., Faulkner L., Gibson A., et al. Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology: 2013; 57 2 727 739
9. Wuillemin N., Adam J., Fontana S., Krähenbühl S., Pichler W. J., Yerly D. HLA haplotype determines hapten or p-i T cell reactivity to flucloxacillin. J Immunol: 2013; 190 10 4956 4964
10. Hautekeete M. L., Horsmans Y., Van Waeyenberge C., et al. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology: 1999; 117 5 1181 1186
11. O'Donohue J., Oien K. A., Donaldson P., et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut: 2000; 47 5 717 720
12. Lucena M. I., Molokhia M., Shen Y., et al. Spanish DILI Registry; EUDRAGENE; DILIN; DILIGEN; International SAEC. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology: 2011; 141 1 338 347
13. Donaldson P. T., Daly A. K., Henderson J., et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol: 2010; 53 6 1049 1053
14. Kindmark A., Jawaid A., Harbron C. G., et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J: 2008; 8 3 186 195 (Pubitemid 351712643)
15. Morgan M. Y., Reshef R., Shah R. R., Oates N. S., Smith R. L., Sherlock S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut: 1984; 25 10 1057 1064 (Pubitemid 14002119)
16. Fromenty B., Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther: 1995; 67 1 101 154
17. Shah R. R. Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics: 2006; 7 6 889 908 (Pubitemid 44446737)
18. Pachkoria K., Lucena M. I., Ruiz-Cabello F., Crespo E., Cabello M. R., Andrade R. J.; Spanish Group for the Study of Drug-Induced Liver Disease (Grupo de Estudio para las Hepatopatías Asociadas a Medicamentos). Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). Br J Pharmacol: 2007; 150 6 808 815 (Pubitemid 46440210)
19. Aithal G. P., Day C. P., Leathart J. BS, Daly A. K. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics: 2000; 10 6 511 518
20. Markova S. M., De Marco T., Bendjilali N., et al. Association of CYP2C9*2 with bosentan-induced liver injury. Clin Pharmacol Ther: 2013; 94 6 678 686
21. Ariyoshi N., Iga Y., Hirata K., et al. Enhanced susceptibility of HLA-mediated ticlopidine-induced idiosyncratic hepatotoxicity by CYP2B6 polymorphism in Japanese. Drug Metab Pharmacokinet: 2010; 25 3 298 306
22. Yimer G., Amogne W., Habtewold A., et al. High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics J: 2012; 12 6 499 506
23. Metushi I. G., Sanders C., Lee W. M., Uetrecht J.; Acute Liver Study Group. Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure. Hepatology: 2014; 59 3 1084 1093
24. Huang Y. S., Chern H. D., Su W. J., et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology: 2003; 37 4 924 930
25. Cho H. J., Koh W. J., Ryu Y. J., et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb): 2007; 87 6 551 556
26. Kim S. H., Kim S. H., Bahn J. W., et al. Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics: 2009; 10 11 1767 1779
27. Vuilleumier N., Rossier M. F., Chiappe A., et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol: 2006; 62 6 423 429 (Pubitemid 44069498)
28. Yamada S., Tang M., Richardson K., et al. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics: 2009; 10 9 1433 1445
29. Bose P. D., Sarma M. P., Medhi S., Das B. C., Husain S. A., Kar P. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J Gastroenterol Hepatol: 2011; 26 2 312 318
30. Santos N. P., Callegari-Jacques S. M., Ribeiro Dos Santos A. K., et al. N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients. Int J Tuberc Lung Dis: 2013; 17 4 499 504
31. Gupta V. H., Amarapurkar D. N., Singh M., et al. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India. J Gastroenterol Hepatol: 2013; 28 8 1368 1374
32. Regan S. L., Maggs J. L., Hammond T. G., Lambert C., Williams D. P., Park B. K. Acyl glucuronides: the good, the bad and the ugly. Biopharm Drug Dispos: 2010; 31 7 367 395
33. Acuña G., Foernzler D., Leong D., et al. Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity. Pharmacogenomics J: 2002; 2 5 327 334 (Pubitemid 35439475)
34. Daly A. K., Aithal G. P., Leathart J. B., Swainsbury R. A., Dang T. S., Day C. P. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology: 2007; 132 1 272 281 (Pubitemid 46108755)
35. Metushi I. G., Cai P., Zhu X., Nakagawa T., Uetrecht J. P. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin Pharmacol Ther: 2011; 89 6 911 914
36. Eichelbaum M., Musch E., Castroparra M., Vonsassen W. Isoniazid hepatotoxicity in relation to acetylator phenotype and isoniazid metabolism. Br J Clin Pharmacol: 1982; 14 4 575 -P576
37. Grönhagen-Riska C., Hellstrom P. E., Fröseth B. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am Rev Respir Dis: 1978; 118 3 461 466 (Pubitemid 9027187)
38. Dickinson D. S., Bailey W. C., Hirschowitz B. I., Soong S. J., Eidus L., Hodgkin M. M. Risk factors for isoniazid (NIH)-induced liver dysfunction. J Clin Gastroenterol: 1981; 3 3 271 279 (Pubitemid 11053230)
39. Mitchell J. R., Thorgeirsson U. P., Black M., et al. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther: 1975; 18 1 70 79
40. Ohno M., Yamaguchi I., Yamamoto I., et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis: 2000; 4 3 256 261 (Pubitemid 30151575)
41. Huang Y. S., Chern H. D., Su W. J., et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology: 2002; 35 4 883 889
42. Lee S. W., Chung L. S., Huang H. H., Chuang T. Y., Liou Y. H., Wu L. S. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis: 2010; 14 5 622 626
43. Ho H. T., Wang T. H., Hsiong C. H., et al. The NAT2 tag SNP rs1495741 correlates with the susceptibility of antituberculosis drug-induced hepatotoxicity. Pharmacogenet Genomics: 2013; 23 4 200 207
44. Possuelo L. G., Castelan J. A., de Brito T. C., et al. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol: 2008; 64 7 673 681
45. Bozok CetintaŚ V., Erer O. F., Kosova B., et al. Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests. Tuberk Toraks: 2008; 56 1 81 86
46. Chamorro J. G., Castagnino J. P., Musella R. M., et al. Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs. J Gastroenterol Hepatol: 2013; 28 2 323 328
47. Leiro-Fernandez V., Valverde D., Vázquez-Gallardo R., et al. N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians. Int J Tuberc Lung Dis: 2011; 15 10 1403 1408
48. Saukkonen J. J., Cohn D. L., Jasmer R. M., et al. ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med: 2006; 174 8 935 952 (Pubitemid 44564795)
49. Roy B., Chowdhury A., Kundu S., et al. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. J Gastroenterol Hepatol: 2001; 16 9 1033 1037 (Pubitemid 32947147)
50. Huang Y. S., Su W. J., Huang Y. H., et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol: 2007; 47 1 128 134
51. Leiro V., Fernández-Villar A., Valverde D., et al. Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int: 2008; 28 6 835 839 (Pubitemid 351818646)
52. Simon T., Becquemont L., Mary-Krause M., et al. Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther: 2000; 67 4 432 437 (Pubitemid 30246823)
53. Watanabe I., Tomita A., Shimizu M., et al. A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin Pharmacol Ther: 2003; 73 5 435 455 (Pubitemid 36549828)
54. Lucena M. I., Andrade R. J., Martínez C., et al. Spanish Group for the Study of Drug-Induced Liver Disease. Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology: 2008; 48 2 588 596
55. Okada R., Maeda K., Nishiyama T., et al. Involvement of different human glutathione transferase isoforms in the glutathione conjugation of reactive metabolites of troglitazone. Drug Metab Dispos: 2011; 39 12 2290 2297
56. Lucena M. I., García-Martín E., Andrade R. J., et al. Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. Hepatology: 2010; 52 1 303 312
57. Andrews E., Armstrong M., Tugwood J., et al. A role for the pregnane X receptor in flucloxacillin-induced liver injury. Hepatology: 2010; 51 5 1656 1664
58. Kuehl P., Zhang J., Lin Y., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet: 2001; 27 4 383 391 (Pubitemid 32268418)
59. Li T., Yu R. T., Atkins A. R., Downes M., Tukey R. H., Evans R. M. Targeting the pregnane X receptor in liver injury. Expert Opin Ther Targets: 2012; 16 11 1075 1083
60. Li F., Lu J., Cheng J., et al. Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Nat Med: 2013; 19 4 418 420
61. Ahmadian M., Suh J. M., Hah N., et al. PPARγ signaling and metabolism: the good, the bad and the future. Nat Med: 2013; 19 5 557 566
62. Geier A., Wagner M., Dietrich C. G., Trauner M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta: 2007; 1773 3 283 308 (Pubitemid 46275063)
63. Noe J., Kullak-Ublick G. A., Jochum W., et al. Impaired expression and function of the bile salt export pump due to three novel ABCB11 mutations in intrahepatic cholestasis. J Hepatol: 2005; 43 3 536 543 (Pubitemid 41111438)
64. Lang C., Meier Y., Stieger B., et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics: 2007; 17 1 47 60 (Pubitemid 46183791)
65. Bhatnagar P., Day C. P., Aithal G., et al. Genetic variants of hepatic transporters and susceptibility to drug induced liver injury. Toxicology: 2008; 253 1-3 10
66. Haenisch S., Zimmermann U., Dazert E., et al. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J: 2007; 7 1 56 65 (Pubitemid 46322080)
67. Choi J. H., Ahn B. M., Yi J., et al. MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet Genomics: 2007; 17 6 403 415 (Pubitemid 46763385)
68. Haas D. W., Bartlett J. A., Andersen J. W., et al. Adult AIDS Clinical Trials Group. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis: 2006; 43 6 783 786 (Pubitemid 44330746)
69. Ritchie M. D., Haas D. W., Motsinger A. A., et al. Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis: 2006; 43 6 779 782 (Pubitemid 44330745)
70. Yuan J., Guo S., Hall D., et al. Nevirapine Toxicogenomics Study Team. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS: 2011; 25 10 1271 1280
71. Holmes M. V., Casas J. P., Hingorani A. D. Putting genomics into practice. BMJ: 2011; 343 d4953
72. Aithal G. P., Watkins P. B., Andrade R. J., et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther: 2011; 89 6 806 815
73. Olson H., Betton G., Robinson D., et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol: 2000; 32 1 56 67
74. Mallal S., Phillips E., Carosi G., et al. PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med: 2008; 358 6 568 579 (Pubitemid 351214284)
75. El Sherrif Y., Potts J. R., Howard M. R., et al. Hepatotoxicity from anabolic androgenic steroids marketed as dietary supplements: contribution from ATP8B1/ABCB11 mutations? Liver Int: 2013; 33 8 1266 1270
76. Alfirevic A., Pirmohamed M. Predictive genetic testing for drug-induced liver injury: considerations of clinical utility. Clin Pharmacol Ther: 2012; 92 3 376 380
77. Chen P., Lin J. J., Lu C. S., et al. Taiwan SJS Consortium. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med: 2011; 364 12 1126 1133
78. Hung S. I., Chung W. H., Liou L. B., et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A: 2005; 102 11 4134 4139
79. Kazeem G. R., Cox C., Aponte J., et al. High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients. Pharmacogenet Genomics: 2009; 19 9 661 665
80. Yip V. L., Marson A. G., Jorgensen A. L., Pirmohamed M., Alfirevic A. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin Pharmacol Ther: 2012; 92 6 757 765
81. Zhang F. R., Liu H., Irwanto A., et al. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med: 2013; 369 17 1620 1628
82. Dubios P. CA. Thiopurine induced pancreatitis genetics working group. The risk of azathioprine-induced pancreatitis depends on genetic variants in the HLA gene region. Gut: 2011; 60 A60
83. Goldstein D. B. Common genetic variation and human traits. N Engl J Med: 2009; 360 17 1696 1698
84. Maher B. Personal genomes: The case of the missing heritability. Nature: 2008; 456 7218 18 21
85. Chung W. H., Hung S. I., Hong H. S., et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature: 2004; 428 6982 486
86. Hughes A. R., Spreen W. R., Mosteller M., et al. Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. Pharmacogenomics J: 2008; 8 6 365 374
87. Liu R., Paxton W. A., Choe S., et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell: 1996; 86 3 367 377 (Pubitemid 26272077)
88. Samson M., Libert F., Doranz B. J., et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature: 1996; 382 6593 722 725
89. Li B., Leal S. M. Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. Am J Hum Genet: 2008; 83 3 311 321
90. Bamshad M. J., Ng S. B., Bigham A. W., et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet: 2011; 12 11 745 755
91. Rakyan V. K., Down T. A., Balding D. J., Beck S. Epigenome-wide association studies for common human diseases. Nat Rev Genet: 2011; 12 8 529 541
92. Murphy S. K., Yang H., Moylan C. A., et al. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. Gastroenterology: 2013; 145 5 1076 1087
93. Greenbaum L. E. From skin cells to hepatocytes: advances in application of iPS cell technology. J Clin Invest: 2010; 120 9 3102 3105
94. Pariente E. A., Hamoud A., Goldfain D., et al. [Hepatitis caused by clometacin (Dupéran). Retrospective study of 30 cases. A model of autoimmune drug-induced hepatitis?]. Gastroenterol Clin Biol: 1989; 13 10 769 774 (Pubitemid 19277787)
95. Hirata K., Takagi H., Yamamoto M., et al. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J: 2008; 8 1 29 33
96. Kurosaki M., Takagi H., Mori M. HLA-A33/B44/DR6 is highly related to intrahepatic cholestasis induced by tiopronin. Dig Dis Sci: 2000; 45 6 1103 1108 (Pubitemid 30409452)
97. Sharma S. K., Balamurugan A., Saha P. K., Pandey R. M., Mehra N. K. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med: 2002; 166 7 916 919 (Pubitemid 35193218)
98. Spraggs C. F., Budde L. R., Briley L. P., et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol: 2011; 29 6 667 673
99. Singer J. B., Lewitzky S., Leroy E., et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet: 2010; 42 8 711 714
100. Phillips E., Bartlett J. A., Sanne I., et al. Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J Acquir Immune Defic Syndr: 2013; 62 2 e55 e57
101. Daly A. K., Day C. P. Genetic association studies in drug-induced liver injury. Drug Metab Rev: 2012; 44 1 116 126